Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanping Hu

Showing results (181-190 of 200) with videos related to

Pageof 20
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib TreatmentJianchun Duan, JiaChen Xu, Zhijie Wang, et al.
Cancer Cell|March 6, 2026
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trialJianchun Duan, Yuping Sun, Qiming Wang, et al.
Cancer Communications (London, England)|June 12, 2026
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 StudyXuezhi Hao, Lin Wang, Yanrong Hao, et al.
Future Oncology (London, England)|January 19, 2023
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS dataParneet Cheema, Byoung Chul Cho, Helano Freitas, et al.
BMC Medicine|February 24, 2023
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)Yuankai Shi, Jianhua Chen, Helong Zhang, et al.
Future Oncology (London, England)|October 30, 2025
Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational studyHua Zhong, Shunjun Jiang, Wenxiu Yao, et al.
The Lancet. Respiratory Medicine|July 26, 2024
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 studyJin-Ji Yang, Jianying Zhou, Si-Yang Maggie Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2023
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 TrialJianchun Duan, Lin Wu, Kunyu Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 7, 2022
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 TrialAnwen Xiong, Shengxiang Ren, Huaimin Liu, et al.
Translational Lung Cancer Research|May 19, 2025
Efficacy and safety of finotonlimab plus docetaxel <i>vs.</i> docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trialBaohui Han, Lin Wu, Runxiang Yang, et al.
Pageof 20

Showing results (181-190 of 200) with videos related to

Sort By:
Pageof 20
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib TreatmentJianchun Duan, JiaChen Xu, Zhijie Wang, et al.
Cancer Cell|March 6, 2026
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trialJianchun Duan, Yuping Sun, Qiming Wang, et al.
Cancer Communications (London, England)|June 12, 2026
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 StudyXuezhi Hao, Lin Wang, Yanrong Hao, et al.
Future Oncology (London, England)|January 19, 2023
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS dataParneet Cheema, Byoung Chul Cho, Helano Freitas, et al.
BMC Medicine|February 24, 2023
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)Yuankai Shi, Jianhua Chen, Helong Zhang, et al.
Future Oncology (London, England)|October 30, 2025
Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational studyHua Zhong, Shunjun Jiang, Wenxiu Yao, et al.
The Lancet. Respiratory Medicine|July 26, 2024
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 studyJin-Ji Yang, Jianying Zhou, Si-Yang Maggie Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2023
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 TrialJianchun Duan, Lin Wu, Kunyu Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 7, 2022
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 TrialAnwen Xiong, Shengxiang Ren, Huaimin Liu, et al.
Translational Lung Cancer Research|May 19, 2025
Efficacy and safety of finotonlimab plus docetaxel <i>vs.</i> docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trialBaohui Han, Lin Wu, Runxiang Yang, et al.
Pageof 20